BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30582993)

  • 1. Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study.
    van Delft LCJ; Nelemans PJ; Jansen MHE; Arits AHMM; Roozeboom MH; Hamid MA; Mosterd K; Kelleners-Smeets NWJ
    J Am Acad Dermatol; 2019 Apr; 80(4):1022-1028. PubMed ID: 30582993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
    Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
    J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
    Lecluse LL; Spuls PI
    Br J Dermatol; 2015 Jan; 172(1):8-10. PubMed ID: 25581584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial.
    Roozeboom MH; Arits AHMM; Mosterd K; Sommer A; Essers BAB; de Rooij MJM; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
    J Invest Dermatol; 2016 Aug; 136(8):1568-1574. PubMed ID: 27113429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
    Roozeboom MH; Nelemans PJ; Mosterd K; Steijlen PM; Arits AH; Kelleners-Smeets NW
    Br J Dermatol; 2015 Mar; 172(3):739-45. PubMed ID: 25066012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
    Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
    Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.
    Jansen MHE; Mosterd K; Arits AHMM; Roozeboom MH; Sommer A; Essers BAB; van Pelt HPA; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
    J Invest Dermatol; 2018 Mar; 138(3):527-533. PubMed ID: 29045820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
    Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
    J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response.
    Fantini F; Greco A; Del Giovane C; Cesinaro AM; Venturini M; Zane C; Surrenti T; Peris K; Calzavara-Pinton PG
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):896-901. PubMed ID: 21054566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
    Foley P; Freeman M; Menter A; Siller G; El-Azhary RA; Gebauer K; Lowe NJ; Jarratt MT; Murrell DF; Rich P; Pariser DM; Oseroff AR; Barnetson R; Anderson C; Kossard S; Gibson LE; Tope WD
    Int J Dermatol; 2009 Nov; 48(11):1236-45. PubMed ID: 20064185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial.
    Surrenti T; De Angelis L; Di Cesare A; Fargnoli MC; Peris K
    Eur J Dermatol; 2007; 17(5):412-5. PubMed ID: 17673385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma.
    Venturini M; Sala R; Gonzàlez S; Calzavara-Pinton PG
    Br J Dermatol; 2013 Jan; 168(1):99-105. PubMed ID: 23013443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial'.
    Nijsten T
    Br J Dermatol; 2015 Jan; 172(1):12. PubMed ID: 25581586
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'.
    Arits A; Nelemans P; Kelleners-Smeets N
    Br J Dermatol; 2015 Jan; 172(1):11-2. PubMed ID: 25581585
    [No Abstract]   [Full Text] [Related]  

  • 16. Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial.
    Nguyen KP; Knuiman GJ; Blokx WAM; Hoogedoorn L; Smits T; Gerritsen MJP
    J Dermatolog Treat; 2019 Mar; 30(2):194-199. PubMed ID: 29862877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
    Szeimies RM
    Dermatol Clin; 2007 Jan; 25(1):89-94. PubMed ID: 17126746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
    Love WE; Bernhard JD; Bordeaux JS
    Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.
    Gracia-Cazaña T; Mascaraque M; Lucena SR; Vera-Álvarez J; González S; Juarranz Á; Gilaberte Y
    PLoS One; 2019; 14(4):e0215537. PubMed ID: 31017970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cells to Surgery Quiz: July 2018.
    Neal DE; Smith RJ; Aberbigbe O; Etzkorn JR
    J Invest Dermatol; 2018 Jul; 138(7):e49. PubMed ID: 29941100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.